{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T07:31:19Z","timestamp":1793431879012,"version":"4.5.0"},"reference-count":96,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T00:00:00Z","timestamp":1638748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","award":["7192218"],"award-info":[{"award-number":["7192218"]}],"id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>\n                    Dasatinib is an oral second-generation tyrosine kinase inhibitor known to be used widely in Philadelphia chromosome-positive (Ph\n                    <jats:sup>+<\/jats:sup>\n                    ) chronic myeloid leukemia (CML) and Ph\n                    <jats:sup>+<\/jats:sup>\n                    acute lymphoblastic leukemia (ALL). Notably, although a high pharmacokinetic variability in patients and an increased risk of pleural effusion are attendant, fixed dosing remains standard practice. Retrospective studies have suggested that dasatinib exposure may be associated with treatment response (efficacy\/safety). Therapeutic drug monitoring (TDM) is gradually becoming a practical tool to achieve the goal of individualized medicine for patients receiving targeted drugs. With the help of TDM, these patients who maintain response while have minimum adverse events may achieve long-term survival. This review summaries current knowledge of the clinical pharmacokinetics variation, exposure-response relationships and analytical method for individualized dosing of dasatinib, in particular with respect to therapeutic drug monitoring. In addition, it highlights the emerging insights into several controversial issues in TDM of dasatinib, with the aim of presenting up-to-date evidence for clinical decision-making and insights for future studies.\n                  <\/jats:p>","DOI":"10.3389\/fphar.2021.797881","type":"journal-article","created":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:23:55Z","timestamp":1638753835000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":38,"title":["Therapeutic Drug Monitoring and Individualized Medicine of Dasatinib: Focus on Clinical Pharmacokinetics and Pharmacodynamics"],"prefix":"10.3389","volume":"12","author":[{"given":"Shiyu","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialu","family":"Bian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianhang","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingxian","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,12,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"119987","DOI":"10.1016\/j.saa.2021.119987","article-title":"Simple and Efficient Spectroscopic-Based Univariate Sequential Methods for Simultaneous Quantitative Analysis of Vandetanib, Dasatinib, and Sorafenib in Pharmaceutical Preparations and Biological Fluids","volume":"260","author":"Abdelhameed","year":"2021","journal-title":"Spectrochim Acta A. Mol. Biomol. Spectrosc."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/j.1471-4159.2007.04808.x","article-title":"Influence of Breast Cancer Resistance Protein (Abcg2) and P-Glycoprotein (Abcb1a) on the Transport of Imatinib Mesylate (Gleevec) across the Mouse Blood-Brain Barrier","volume":"102","author":"Bihorel","year":"2007","journal-title":"J. Neurochem."},{"key":"B3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/bmc.2796","article-title":"Simple Methodology for the Therapeutic Drug Monitoring of the Tyrosine Kinase Inhibitors Dasatinib and Imatinib","volume":"27","author":"Birch","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cca.2011.02.023","article-title":"Simultaneous Determination of Nine Tyrosine Kinase Inhibitors by 96-well Solid-phase Extraction and Ultra Performance LC\/MS-MS","volume":"412","author":"Bouchet","year":"2011","journal-title":"Clin. Chim. Acta"},{"key":"B76","unstructured":"Sprycel: Full Prescribing Information. E. coli2017"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/clpt.2012.73","article-title":"Drug Absorption Interactions between Oral Targeted Anticancer Agents and PPIs: Is pH-dependent Solubility the Achilles Heel of Targeted Therapy?","volume":"92","author":"Budha","year":"2012","journal-title":"Clin. Pharmacol. Ther."},{"key":"B7","article-title":"Atypical Pharmacokinetic Profiles Observed with Dasatinib Reference Listed Drug Product in Bioequivalence Studies","author":"Chandani","year":"2017"},{"key":"B8","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1124\/jpet.109.154781","article-title":"P-glycoprotein and Breast Cancer Resistance Protein Influence Brain Distribution of Dasatinib","volume":"330","author":"Chen","year":"2009","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.3389\/fphar.2019.01232","article-title":"Immunomodulatory Activity of Tyrosine Kinase Inhibitors to Elicit Cytotoxicity against Cancer and Viral Infection","volume":"10","author":"Climent","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B68","unstructured":"The Effect of Omeprazole on the Pharmacokinetics of Dasatinib (BMS-354825) in Healthy Subjects. E. coli2009"},{"key":"B10","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) Targets an Earlier Progenitor Population Than Imatinib in Primary CML but Does Not Eliminate the Quiescent Fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1182\/blood-2006-09-046888","article-title":"Dasatinib Induces Complete Hematologic and Cytogenetic Responses in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Blast Crisis","volume":"109","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1007\/s00216-012-5970-2","article-title":"An Automated Method for the Measurement of a Range of Tyrosine Kinase Inhibitors in Human Plasma or Serum Using Turbulent Flow Liquid Chromatography-Tandem Mass Spectrometry","volume":"403","author":"Couchman","year":"2012","journal-title":"Anal. Bioanal. Chem."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1177\/0091270008320604","article-title":"Importance of Characterizing Determinants of Variability in Exposure: Application to Dasatinib in Subjects with Chronic Myeloid Leukemia","volume":"48","author":"Dai","year":"2008","journal-title":"J. Clin. Pharmacol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2217\/pgs-2016-0012","article-title":"ABCB1 1199G>A Polymorphism (Rs2229109) Affects the Transport of Imatinib, Nilotinib and Dasatinib","volume":"17","author":"Dessilly","year":"2016","journal-title":"Pharmacogenomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s13238-018-0547-2","article-title":"Pharmacomicrobiomics: a Novel Route towards Personalized Medicine?","volume":"9","author":"Doestzada","year":"2018","journal-title":"Protein Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"e0192180","DOI":"10.1371\/journal.pone.0192180","article-title":"ABCC6 Plays a Significant Role in the Transport of Nilotinib and Dasatinib, and Contributes to TKI Resistance In Vitro, in Both Cell Lines and Primary Patient Mononuclear Cells","volume":"13","author":"Eadie","year":"2018","journal-title":"PLoS One"},{"key":"B17","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1177\/0091270009333854","article-title":"Phase I Study of the Effect of Gastric Acid pH Modulators on the Bioavailability of Oral Dasatinib in Healthy Subjects","volume":"49","author":"Eley","year":"2009","journal-title":"J. Clin. Pharmacol."},{"key":"B18","unstructured":"Sprycel: EPAR \u2013 Scientific Discussion. E. coli2006"},{"key":"B19","doi-asserted-by":"publisher","first-page":"121851","DOI":"10.1016\/j.jchromb.2019.121851","article-title":"Simultaneous Quantitative Determination of Seven Novel Tyrosine Kinase Inhibitors in Plasma by a Validated UPLC-MS\/MS Method and its Application to Human Microsomal Metabolic Stability Study","volume":"1136","author":"Ezzeldin","year":"2020","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/j.1365-2141.2008.07433.x","article-title":"Dasatinib Inhibits the Proliferation and Function of CD4+CD25+ Regulatory T Cells","volume":"144","author":"Fei","year":"2009","journal-title":"Br. J. Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jpba.2011.09.008","article-title":"A Validated LC-MS\/MS Assay for the Simultaneous Determination of the Anti-leukemic Agent Dasatinib and Two Pharmacologically Active Metabolites in Human Plasma: Application to a Clinical Pharmacokinetic Study","volume":"58","author":"Furlong","year":"2012","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1182\/blood-2007-10-116236","article-title":"Effective Dasatinib Uptake May Occur without Human Organic Cation Transporter 1 (hOCT1): Implications for the Treatment of Imatinib-Resistant Chronic Myeloid Leukemia","volume":"112","author":"Giannoudis","year":"2008","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4143","DOI":"10.1182\/blood-2006-09-046839","article-title":"Dasatinib Induces Significant Hematologic and Cytogenetic Responses in Patients with Imatinib-Resistant or -intolerant Chronic Myeloid Leukemia in Accelerated Phase","volume":"109","author":"Guilhot","year":"2007","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/j.1365-2125.2012.04422.x","article-title":"Prediction of Free Imatinib Concentrations Based on Total Plasma Concentrations in Patients with Gastrointestinal Stromal Tumours","volume":"75","author":"Haouala","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1016\/j.jchromb.2009.04.045","article-title":"Therapeutic Drug Monitoring of the New Targeted Anticancer Agents Imatinib, Nilotinib, Dasatinib, Sunitinib, Sorafenib and Lapatinib by LC Tandem Mass Spectrometry","volume":"877","author":"Haouala","year":"2009","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/j.1476-5381.2009.00383.x","article-title":"Interaction of Nilotinib, Dasatinib and Bosutinib with ABCB1 and ABCG2: Implications for Altered Anti-cancer Effects and Pharmacological Properties","volume":"158","author":"Hegedus","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"e5124","DOI":"10.1002\/bmc.5124","article-title":"High-throughput Liquid Chromatography\/electrospray Ionization-Tandem Mass Spectrometry Method Using In-Source Collision-Induced Dissociation for Simultaneous Quantification of Imatinib, Dasatinib, Bosutinib, Nilotinib, and Ibrutinib in Human Plasma","volume":"35","author":"Hirasawa","year":"2021","journal-title":"Biomed. Chromatogr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-07-5095","article-title":"Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications","volume":"14","author":"Hiwase","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"B29","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2009.242","article-title":"Nilotinib-mediated Inhibition of ABCB1 Increases Intracellular Concentration of Dasatinib in CML Cells: Implications for Combination TKI Therapy","volume":"24","author":"Hiwase","year":"2010","journal-title":"Leukemia"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib Induces Notable Hematologic and Cytogenetic Responses in Chronic-phase Chronic Myeloid Leukemia after Failure of Imatinib Therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"52","DOI":"10.14712\/23362936.2019.10","article-title":"Pharmacokinetics of Dasatinib","volume":"120","author":"Horinkova","year":"2019","journal-title":"Prague Med. Rep."},{"key":"B32","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fimmu.2017.00469","article-title":"Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-free Remission","volume":"8","author":"Hughes","year":"2017","journal-title":"Front. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/FTD.0000000000000357","article-title":"Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS\/MS","volume":"39","author":"Huynh","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"B34","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00228-015-1968-y","article-title":"Pharmacokinetics and Pharmacodynamics of Dasatinib in the Chronic Phase of Newly Diagnosed Chronic Myeloid Leukemia","volume":"72","author":"Ishida","year":"2016","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1097\/FTD.0000000000000639","article-title":"Evaluation of Medication Adherence and Pharmacokinetics of Dasatinib for Earlier Molecular Response in Japanese Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Pilot Study","volume":"41","author":"Iwamoto","year":"2019","journal-title":"Ther. Drug Monit."},{"key":"B36","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical Pharmacokinetics and In Vitro Metabolism of Dasatinib (BMS-354825): a Potent Oral Multi-Targeted Kinase Inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1007\/s00280-007-0478-8","article-title":"Preclinical Pharmacokinetics and In Vitro Metabolism of Dasatinib (BMS-354825): a Potent Oral Multi-Targeted Kinase Inhibitor against SRC and BCR-ABL","volume":"61","author":"Kamath","year":"","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1182\/blood-2006-11-056028","article-title":"Dasatinib or High-Dose Imatinib for Chronic-phase Chronic Myeloid Leukemia after Failure of First-Line Imatinib: a Randomized Phase 2 Trial","volume":"109","author":"Kantarjian","year":"2007","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus Imatinib in Newly Diagnosed Chronic-phase Chronic Myeloid Leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"B40","doi-asserted-by":"publisher","first-page":"462484","DOI":"10.1016\/j.chroma.2021.462484","article-title":"Trace-level Monitoring of Anti-cancer Drug Residues in Wastewater and Biological Samples by Thin-Film Solid-phase Micro-extraction Using Electrospun polyfam\/Co-MOF-74 Composite Nanofibers Prior to Liquid Chromatography Analysis","volume":"1655","author":"Khodayari","year":"2021","journal-title":"J. Chromatogr. A."},{"key":"B41","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1177\/1078155217692152","article-title":"Pepsi\u00ae or Coke\u00ae? Influence of Acid on Dasatinib Absorption","volume":"24","author":"Knoebel","year":"2018","journal-title":"J. Oncol. Pharm. Pract."},{"key":"B42","doi-asserted-by":"publisher","first-page":"120450","DOI":"10.1016\/j.talanta.2019.120450","article-title":"Effective Quantification of 11 Tyrosine Kinase Inhibitors and Caffeine in Human Plasma by Validated LC-MS\/MS Method with Potent Phospholipids Clean-Up Procedure. Application to Therapeutic Drug Monitoring","volume":"208","author":"Koller","year":"2020","journal-title":"Talanta"},{"key":"B43","doi-asserted-by":"publisher","first-page":"2344","DOI":"10.1158\/1078-0432.CCR-08-2253","article-title":"Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment","volume":"15","author":"Lagas","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"B44","first-page":"37","article-title":"Influencing Factors of Serum Valparaiso Acid Concentration in Children with Epilepsy Based on Multivariate Linear Regression","volume":"26","author":"Lai","year":"2020","journal-title":"J. Pediatr. Pharm."},{"key":"B45","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40262-020-00872-4","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Dasatinib","volume":"59","author":"Lev\u00eaque","year":"2020","journal-title":"Clin. Pharmacokinet."},{"key":"B46","first-page":"29","volume-title":"Dasatinib","author":"Lindauer","year":"2018"},{"key":"B47","doi-asserted-by":"publisher","first-page":"113968","DOI":"10.1016\/j.jpba.2021.113968","article-title":"Development and Clinical Validation of a Simple and Fast UPLC-ESI-MS\/MS Method for Simultaneous Quantification of Nine Kinase Inhibitors and Two Antiandrogen Drugs in Human Plasma: Interest for Their Therapeutic Drug Monitoring","volume":"197","author":"Llopis","year":"2021","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B48","doi-asserted-by":"publisher","first-page":"6658","DOI":"10.1021\/jm049486a","article-title":"Discovery of N-(2-chloro-6-methyl- Phenyl)-2-(6-(4-(2-Hydroxyethyl)- Piperazin-1-Yl)-2-Methylpyrimidin-4- Ylamino)thiazole-5-Carboxamide (BMS-354825), a Dual Src\/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays","volume":"47","author":"Lombardo","year":"2004","journal-title":"J. Med. Chem."},{"key":"B49","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1021\/mp400283j","article-title":"Investigation of the Rat Model for Preclinical Evaluation of pH-dependent Oral Absorption in Humans","volume":"10","author":"Lubach","year":"2013","journal-title":"Mol. Pharm."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s00280-008-0699-5","article-title":"Identification and Validation of Phospho-SRC, a Novel and Potential Pharmacodynamic Biomarker for Dasatinib (SPRYCEL), a Multi-Targeted Kinase Inhibitor","volume":"62","author":"Luo","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure","volume":"12","author":"Luo","year":"","journal-title":"Clin. Cancer Res."},{"key":"B52","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-06-1112","article-title":"Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure","volume":"12","author":"Luo","year":"","journal-title":"Clin. Cancer Res."},{"key":"B53","doi-asserted-by":"publisher","first-page":"e0199208","DOI":"10.1371\/journal.pone.0199208","article-title":"Validated UPLC-MS\/MS Method for the Quantification of Dasatinib in Plasma: Application to Pharmacokinetic Interaction Studies with Nutraceuticals in Wistar Rats","volume":"13","author":"Maher","year":"2018","journal-title":"PLoS One"},{"key":"B54","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00280-012-1900-4","article-title":"H2-receptor Antagonist Influences Dasatinib Pharmacokinetics in a Patient with Philadelphia-positive Acute Lymphoblastic Leukemia","volume":"70","author":"Matsuoka","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.jpba.2017.11.060","article-title":"High Throughput Routine Determination of 17 Tyrosine Kinase Inhibitors by LC-MS\/MS","volume":"150","author":"Merienne","year":"2018","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B56","doi-asserted-by":"publisher","first-page":"S1592","DOI":"10.21037\/tcr.2017.09.10","article-title":"Role of CYP3A4 in Kinase Inhibitor Metabolism and Assessment of CYP3A4 Activity","volume":"6","author":"Mikus","year":"2017","journal-title":"Transl. Cancer Res."},{"key":"B57","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.11406\/rinketsu.60.1140","article-title":"Management Using the Plasma Concentration of Tyrosine Kinase Inhibitors for the Treatment of Chronic Myelogenous Leukemia: an Update","volume":"60","author":"Miura","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"B58","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.dmpk.2015.09.002","article-title":"Routine Therapeutic Drug Monitoring of Tyrosine Kinase Inhibitors by HPLC-UV or LC-MS\/MS Methods","volume":"31","author":"Miura","year":"2016","journal-title":"Drug Metab. Pharmacokinet."},{"key":"B59","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s10147-018-1300-9","article-title":"Plasma Concentrations of Dasatinib Have a Clinical Impact on the Frequency of Dasatinib Dose Reduction and Interruption in Chronic Myeloid Leukemia: an Analysis of the DARIA 01 Study","volume":"23","author":"Mizuta","year":"2018","journal-title":"Int. J. Clin. Oncol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"121928","DOI":"10.1016\/j.jchromb.2019.121928","article-title":"Novel High-Performance Liquid Chromatography-Tandem Mass Spectrometry Method for Simultaneous Quantification of BCR-ABL and Bruton's Tyrosine Kinase Inhibitors and Their Three Active Metabolites in Human Plasma","volume":"1137","author":"Mukai","year":"2020","journal-title":"J. Chromatogr. B Analyt Technol. Biomed. Life Sci."},{"key":"B61","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1038\/leu.2012.348","article-title":"Rapid Mobilization of Cytotoxic Lymphocytes Induced by Dasatinib Therapy","volume":"27","author":"Mustjoki","year":"2013","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3356","DOI":"10.1158\/0008-5472.CAN-12-3904","article-title":"Threshold Levels of ABL Tyrosine Kinase Inhibitors Retained in Chronic Myeloid Leukemia Cells Determine Their Commitment to Apoptosis","volume":"73","author":"O'hare","year":"2013","journal-title":"Cancer Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/clpt.1982.89","article-title":"Interaction between Valproic Acid and Aspirin in Epileptic Children: Serum Protein Binding and Metabolic Effects","volume":"31","author":"Orr","year":"1982","journal-title":"Clin. Pharmacol. Ther."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1111\/bcp.12895","article-title":"Effect of Esomeprazole on the Oral Absorption of Dasatinib in a Patient with Philadelphia-positive Acute Lymphoblastic Leukemia","volume":"81","author":"Pape","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s00210-001-0489-7","article-title":"Interaction of Omeprazole, Lansoprazole and Pantoprazole with P-Glycoprotein","volume":"364","author":"Pauli-Magnus","year":"2001","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol."},{"key":"B66","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1124\/dmd.108.024646","article-title":"An Unexpected Synergist Role of P-Glycoprotein and Breast Cancer Resistance Protein on the central Nervous System Penetration of the Tyrosine Kinase Inhibitor Lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; GW572016)","volume":"37","author":"Polli","year":"2009","journal-title":"Drug Metab. Dispos"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1182\/blood-2008-02-140665","article-title":"Dasatinib Crosses the Blood-Brain Barrier and Is an Efficient Therapy for central Nervous System Philadelphia Chromosome-Positive Leukemia","volume":"112","author":"Porkka","year":"2008","journal-title":"Blood"},{"key":"B69","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","article-title":"Dasatinib Dose Optimisation Based on Therapeutic Drug Monitoring Reduces Pleural Effusion Rates in Chronic Myeloid Leukaemia Patients","volume":"194","author":"Rousselot","year":"2021","journal-title":"Br. J. Haematol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1200\/JCO.2007.14.9260","article-title":"Intermittent Target Inhibition with Dasatinib 100 Mg once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-phase Chronic Myeloid Leukemia","volume":"26","author":"Shah","year":"","journal-title":"J. Clin. Oncol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.ccr.2008.11.001","article-title":"Transient Potent BCR-ABL Inhibition Is Sufficient to Commit Chronic Myeloid Leukemia Cells Irreversibly to Apoptosis","volume":"14","author":"Shah","year":"","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2009.011452","article-title":"Potent, Transient Inhibition of BCR-ABL with Dasatinib 100 Mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients with Resistance, Suboptimal Response or Intolerance to Imatinib","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","article-title":"Dasatinib in Imatinib-Resistant or -intolerant Chronic-phase, Chronic Myeloid Leukemia Patients: 7-year Follow-Up of Study CA180-034","volume":"91","author":"Shah","year":"2016","journal-title":"Am. J. Hematol."},{"key":"B74","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2147\/PGPM.S45522","article-title":"ABCB1 Haplotypes Do Not Influence Transport or Efficacy of Tyrosine Kinase Inhibitors In Vitro","volume":"6","author":"Skoglund","year":"2013","journal-title":"Pharmgenomics Pers Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"3459","DOI":"10.1182\/blood-2007-10-113969","article-title":"Acute Dasatinib Exposure Commits Bcr-abl-dependent Cells to Apoptosis","volume":"114","author":"Snead","year":"2009","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/ftd.0000000000000922","article-title":"Development of a Sensitive and High-Throughput Assay for Simultaneous Quantification of Five Tyrosine Kinase Inhibitors and Two Active Metabolites in Human Plasma Using Ultra-high Performance Liquid Chromatography Coupled to Tandem Mass Spectrometry","author":"Sumimoto","year":"2021","journal-title":"Ther. Drug Monit"},{"key":"B78","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00280-011-1797-3","article-title":"Influence of H2-Receptor Antagonists and Proton Pump Inhibitors on Dasatinib Pharmacokinetics in Japanese Leukemia Patients","volume":"69","author":"Takahashi","year":"","journal-title":"Cancer Chemother. Pharmacol."},{"key":"B79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/1756-8722-5-23","article-title":"Pharmacokinetics of Dasatinib for Philadelphia-positive Acute Lymphocytic Leukemia with Acquired T315I Mutation","volume":"5","author":"Takahashi","year":"","journal-title":"J. Hematol. Oncol."},{"key":"B80","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa055229","article-title":"Dasatinib in Imatinib-Resistant Philadelphia Chromosome-Positive Leukemias","volume":"354","author":"Talpaz","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"B81","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ejps.2015.05.013","article-title":"In Vitro dissolution Methodology, Mini-Gastrointestinal Simulator (mGIS), Predicts Better In Vivo Dissolution of a Weak Base Drug, Dasatinib","volume":"76","author":"Tsume","year":"2015","journal-title":"Eur. J. Pharm. Sci."},{"key":"B82","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/hon.2034","article-title":"Direct Effect of Dasatinib on Proliferation and Cytotoxicity of Natural Killer Cells in In Vitro Study","volume":"31","author":"Uchiyama","year":"2013","journal-title":"Hematol. Oncol."},{"key":"B83","doi-asserted-by":"publisher","first-page":"3331","DOI":"10.1182\/blood-2012-08-452409","article-title":"Integrating In Vitro Sensitivity and Dose-Response Slope Is Predictive of Clinical Response to ABL Kinase Inhibitors in Chronic Myeloid Leukemia","volume":"122","author":"Vainstein","year":"2013","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1002\/cpt.787","article-title":"Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology","volume":"102","author":"Verheijen","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"B85","doi-asserted-by":"publisher","first-page":"122140","DOI":"10.1016\/j.talanta.2021.122140","article-title":"Quantification of Eight Hematological Tyrosine Kinase Inhibitors in Both Plasma and Whole Blood by a Validated LC-MS\/MS Method","volume":"226","author":"Verougstraete","year":"2021","journal-title":"Talanta"},{"key":"B86","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2147\/CPAA.S42796","article-title":"Differential Effects of Dosing Regimen on the Safety and Efficacy of Dasatinib: Retrospective Exposure-Response Analysis of a Phase III Study","volume":"5","author":"Wang","year":"2013","journal-title":"Clin. Pharmacol."},{"key":"B87","doi-asserted-by":"publisher","first-page":"3590","DOI":"10.1200\/jco.2008.26.15_suppl.3590","article-title":"Dasatinib Pharmacokinetics and Exposure-Response (E-R): Relationship to Safety and Efficacy in Patients (Pts) with Chronic Myeloid Leukemia (CML)","volume":"26","author":"Wang","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1136\/gutjnl-2019-320204","article-title":"Interaction between Drugs and the Gut Microbiome","volume":"69","author":"Weersma","year":"2020","journal-title":"Gut"},{"key":"B89","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/j.ejca.2014.04.015","article-title":"Review of Therapeutic Drug Monitoring of Anticancer Drugs Part Two - Targeted Therapies","volume":"50","author":"Widmer","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/FTD.0000000000000406","article-title":"Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and its Application to Therapeutic Drug Monitoring","volume":"39","author":"Wojnicz","year":"2017","journal-title":"Ther. Drug Monit."},{"key":"B91","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1208\/s12248-014-9673-9","article-title":"The Use of Betaine HCl to Enhance Dasatinib Absorption in Healthy Volunteers with Rabeprazole-Induced Hypochlorhydria","volume":"16","author":"Yago","year":"2014","journal-title":"Aaps j"},{"key":"B92","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s40262-014-0137-2","article-title":"Practical Guidelines for Therapeutic Drug Monitoring of Anticancer Tyrosine Kinase Inhibitors: Focus on the Pharmacokinetic Targets","volume":"53","author":"Yu","year":"2014","journal-title":"Clin. Pharmacokinet."},{"key":"B93","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2174\/1389200219666180129151948","article-title":"Pharmacokinetics, Pharmacodynamics and Pharmacogenetics of Tacrolimus in Kidney Transplantation","volume":"19","author":"Yu","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"B94","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jpha.2017.07.009","article-title":"A Validated UPLC-MS\/MS Method for Simultaneous Determination of Imatinib, Dasatinib and Nilotinib in Human Plasma","volume":"7","author":"Zeng","year":"2017","journal-title":"J. Pharm. Anal."},{"key":"B95","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00228-009-0726-4","article-title":"CYP3A4*1G Genetic Polymorphism Influences CYP3A Activity and Response to Fentanyl in Chinese Gynecologic Patients","volume":"66","author":"Zhang","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B96","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.3109\/10428194.2012.745933","article-title":"Isolated central Nervous System Relapse in Patient with Blast-Crisis Chronic Myeloid Leukemia in Durable Complete Cytogenetic Remission on Dasatinib Treatment: Pharmacokinetics and ABL Mutation Analysis in Cerebrospinal Fluid","volume":"54","author":"Zhou","year":"2013","journal-title":"Leuk. Lymphoma"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.797881\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,6]],"date-time":"2021-12-06T01:24:01Z","timestamp":1638753841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.797881\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,6]]},"references-count":96,"alternative-id":["10.3389\/fphar.2021.797881"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.797881","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,6]]},"article-number":"797881"}}